effect of oral NAC in hemodialysis patients

Not Applicable

• Conditions: ephropathy.; Extracorporeal dialysis

• Registration Number: IRCT2016111529812N2
• Lead Sponsor: Vice Chancellor for research of University of Medical Sciences and Health Services, Yazd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

Inclusion critera: patients undergone hemodialysis that received hemodialysis for more than 3 month with 3 sessions per week. Exclusion criteria: Patients undergone hemodialysis with venous catheter; symptoms of active infection in one month before starting the study and during the study; rising liver enzymes(ALT and AST); blood transfusion during the study; collagen vascular diseases were the etiology of end stage renal disease; age lesser than 18 –year- old, use of corticosteroid and immunosuppressive drugs; history of myocardial infarction or stroke in 3 month before starting the study; history of intolerance or allergy to NAC.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hs-CRP. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: Mg/dl.;MDA. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: µmol/dl.;Albomin. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: g/dl.;Cholesterol. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: Mg/dl.;Triglycerides. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: Mg/dl.;Hb-A1C. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: g/dl.;Calcium. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: Mg/dl.;Phosphorus. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: Mg/dl.